Is Renalytix the best penny stock to buy today?

The Renalytix share price erupted this week as the AI diagnostics firm received a takeover bid. But is it too late to buy this penny stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A pastel colored growing graph with rising rocket.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny stocks have a reputation for being volatile. And in 2024, it seems Renalytix (LSE:RENX) is carrying on with this legacy. Shares of the biotech diagnostics firm have exploded by more than 200% since the start of the year. And looking specifically at the past month, the group’s market capitalisation has surged by more than 360%!

What’s behind these skyrocketing returns? And is this business one of the best penny stocks to buy now? Let’s explore.

Opportunities in kidney disease

The world of healthcare diagnostics is vast and highly specialised. But in the case of Renalytix, the group is focused squarely on just one aspect – kidney disease. Using its KidneyIntelX AI-powered platform, clinical teams can catch early signs of kidney disease, resulting in better outcomes for patients.

The firm still has a long way to go before turning a profit. But unlike many penny stocks, Renalytix is already generating revenue from its technology. Considering kidney disease affects more people than cancer worldwide, the long-term potential is understandably exciting. And it seems the latest round of explosive share price growth is seen as further proof of this.

Earlier this week, the company received an unsolicited takeover bid. Another undisclosed diagnostics enterprise has taken an interest in Renalytix’s technology and submitted an offer to acquire the entire business. In response, management has launched a formal sale process, inviting other companies to make an offer.

The likely goal is to bring in other interested parties, triggering a bidding war that will drive the acquisition price higher, resulting in more money for shareholders. With that in mind, seeing the penny stock explode on this announcement isn’t a massive surprise. But is it too late to buy?

Investing versus speculation

Typically, when a company announces it’s entertaining an acquisition offer, the share price will jump to a point that’s near the offer price. But in the case of Renalytix, the offer is currently unknown. As such, it’s impossible to know whether the buyout price will be above or below the current market capitalisation of the company.

Yet if a bidding war were to commence, then this penny stock could continue to surge even higher. In this scenario, snapping up some shares today could prove to be a lucrative decision.

However, it’s important to realise that making such an investment right now is akin to pure speculation. After all, there’s no guarantee other companies will come in to make an offer. At the same time, the original offer isn’t set in stone and may not necessarily materialise.

But what if investors want to gain exposure to the kidney diagnostics market through this business? If an investment thesis is based on the underlying company rather than the potential for an acquisition, then some caution may be necessary, in my opinion.

Renalytix’s technology seems to be making waves. That’s an encouraging sight for any business. However, with the penny stock priced as if an acquisition is guaranteed, the valuation and fundamentals are currently out of whack.

Analyst forecasts for its 2024 fiscal year ending in June predict that sales will reach $6.15m (£4.85m). That puts the forward price-to-sales ratio at around 10 times. Needless to say, that’s not cheap, especially for a business that still has a lot to prove.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

The flag of the United States of America flying in front of the Capitol building
Investing Articles

3 top S&P 500 growth shares to consider buying for a Stocks and Shares ISA in 2025

Edward Sheldon has picked out three S&P 500 stocks that he believes will provide attractive returns for investors in the…

Read more »

Growth Shares

Can the red hot Scottish Mortgage share price smash the FTSE 100 again in 2025?

The Scottish Mortgage share price moved substantially higher in 2024. Edward Sheldon expects further gains next year and in the…

Read more »

Inflation in newspapers
Investing Articles

2 inflation-resistant growth stocks to consider buying in 2025

Rising prices are back on the macroeconomic radar, meaning growth prospects are even more important for investors looking for stocks…

Read more »

Investing Articles

Why I’ll be avoiding BT shares like the plague in 2025

BT shares are currently around 23% below the average analyst price target for the stock. But Stephen Wright doesn’t see…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

5 Warren Buffett investing moves I’ll make in 2025

I’m planning to channel Warren Buffett in 2025. I won’t necessarily buy the same stocks as him, but I’ll track…

Read more »

Investing Articles

Here’s why 2025 could be make-or-break for this FTSE 100 stock

Diageo is renowned for having some of the strongest brands of any FTSE 100 company. But Stephen Wright thinks it’s…

Read more »

Investing Articles

1 massive Stocks and Shares ISA mistake to avoid in 2025!

Harvey Jones kept making the same investment mistake in 2024. Now he aims to put it right when buying companies…

Read more »

Value Shares

Can Lloyds shares double investors’ money in 2025?

Lloyds shares look dirt cheap today. But are they cheap enough to be able to double in price in 2025?…

Read more »